Ritter Pharmaceuticals, Inc. (RTTR) Reaches $0.29 52 Week Low; Intrexon (XON) Shorts Up By 4.64%

December 6, 2017 - By Henry Gaston

Intrexon Corporation (NYSE:XON) had an increase of 4.64% in short interest. XON’s SI was 19.53 million shares in December as released by FINRA. Its up 4.64% from 18.66M shares previously. With 1.08 million avg volume, 18 days are for Intrexon Corporation (NYSE:XON)’s short sellers to cover XON’s short positions. The SI to Intrexon Corporation’s float is 35.14%. The stock decreased 0.85% or $0.11 during the last trading session, reaching $12.83. About 298,289 shares traded. Intrexon Corporation (NYSE:XON) has declined 10.60% since December 6, 2016 and is downtrending. It has underperformed by 27.30% the S&P500.

The stock of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) hit a new 52-week low and has $0.27 target or 8.00% below today’s $0.29 share price. The 6 months bearish chart indicates high risk for the $14.53 million company. The 1-year low was reported on Dec, 6 by Barchart.com. If the $0.27 price target is reached, the company will be worth $1.16 million less. The stock decreased 4.46% or $0.0137 during the last trading session, reaching $0.2935. About 585,111 shares traded. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has declined 56.21% since December 6, 2016 and is downtrending. It has underperformed by 72.91% the S&P500.




Analysts await Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) to report earnings on February, 26. They expect $-0.05 earnings per share, up 93.24% or $0.69 from last year’s $-0.74 per share. After $-0.14 actual earnings per share reported by Ritter Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -64.29% EPS growth.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company has market cap of $14.53 million. The Company’s lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. It currently has negative earnings. The companyÂ’s product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.

Among 5 analysts covering Ritter Pharmaceuticals (NASDAQ:RTTR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ritter Pharmaceuticals had 9 analyst reports since December 2, 2015 according to SRatingsIntel. H.C. Wainwright maintained Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) on Monday, October 23 with “Buy” rating. The firm has “Buy” rating by Maxim Group given on Thursday, April 14. Maxim Group maintained Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) on Friday, August 4 with “Hold” rating. Chardan Capital Markets maintained Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) on Tuesday, October 25 with “Buy” rating. Chardan Capital Markets initiated the stock with “Buy” rating in Wednesday, December 2 report. On Monday, June 5 the stock rating was maintained by Roth Capital with “Buy”. On Wednesday, July 5 the stock rating was maintained by Maxim Group with “Hold”. The stock of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) earned “Buy” rating by Rodman & Renshaw on Wednesday, January 4.

Among 7 analysts covering Intrexon (NYSE:XON), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Intrexon had 17 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was maintained by Wunderlich with “Buy” on Monday, October 19. The stock of Intrexon Corporation (NYSE:XON) earned “Buy” rating by Stifel Nicolaus on Friday, November 10. The stock of Intrexon Corporation (NYSE:XON) has “Neutral” rating given on Monday, January 25 by Mizuho. The stock of Intrexon Corporation (NYSE:XON) has “Buy” rating given on Wednesday, April 5 by Stifel Nicolaus. As per Tuesday, August 11, the company rating was downgraded by Mizuho. The stock of Intrexon Corporation (NYSE:XON) has “Buy” rating given on Tuesday, August 11 by Wunderlich. JP Morgan downgraded Intrexon Corporation (NYSE:XON) rating on Tuesday, August 11. JP Morgan has “Overweight” rating and $55 target. The firm has “Buy” rating by Northland Capital given on Thursday, October 5. The rating was initiated by Northland Capital on Thursday, December 29 with “Outperform”. The stock of Intrexon Corporation (NYSE:XON) has “Market Outperform” rating given on Tuesday, May 3 by JMP Securities.

Intrexon Corporation operates in the synthetic biology field in the United States. The company has market cap of $1.55 billion. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It currently has negative earnings. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform.

Investors sentiment decreased to 0.86 in 2017 Q2. Its down 0.04, from 0.9 in 2017Q1. It turned negative, as 12 investors sold Intrexon Corporation shares while 59 reduced holdings. 26 funds opened positions while 35 raised stakes. 98.10 million shares or 0.48% less from 98.57 million shares in 2017Q1 were reported. Barclays Plc invested in 0% or 185 shares. Us National Bank & Trust De accumulated 200 shares. Advisory Serv Networks Ltd Com owns 1,282 shares for 0% of their portfolio. Great West Life Assurance Can holds 0% in Intrexon Corporation (NYSE:XON) or 6,671 shares. Price T Rowe Assoc Incorporated Md holds 0% in Intrexon Corporation (NYSE:XON) or 23,537 shares. 104,129 were reported by Wells Fargo Mn. Opus Point Prtn Ltd Liability Corp has 0.41% invested in Intrexon Corporation (NYSE:XON). Zurcher Kantonalbank (Zurich Cantonalbank) reported 2,404 shares or 0% of all its holdings. 3.74 million were accumulated by Iridian Asset Mgmt Ltd Ct. National Planning Corporation stated it has 12,958 shares. Dixon Hubard Feinour And Brown Incorporated Va owns 70,604 shares or 0.49% of their US portfolio. Janney Montgomery Scott Ltd Liability Company holds 0.07% of its portfolio in Intrexon Corporation (NYSE:XON) for 222,563 shares. 18,180 are owned by Bluecrest Mngmt Limited. Fmr Limited Liability Corp holds 0.02% or 5.60 million shares in its portfolio. Tower Research Capital Llc (Trc) stated it has 0.01% of its portfolio in Intrexon Corporation (NYSE:XON).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.